ImmunityBio
  • Our Science
    • Platforms
    • Pipeline
    • Expanded Access
    • Research
  • Unique Approach
    • Patients
    • Trial Investigators
    • Researchers
  • Therapies
    • Bladder Cancer
    • Glioblastoma
    • Lynch Syndrome
    • Non-Small Cell Lung Cancer
    • Pancreatic Cancer
    • COVID-19
    • HIV
  • Our Company
    • About Us
    • Investors
    • News
    • Contact
  • Careers
  • Get Started
    • Find a Trial
    • Become a Trial
      Investigator
    • License our Cells
Select Page

Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer

Jul 7, 2023 | Bladder Cancer

IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

Jun 29, 2023 | Bladder Cancer

QUILT 3032: Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle- invasive bladder cancer (NMIBC)

QUILT 3032: Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle- invasive bladder cancer (NMIBC)

Jun 15, 2022 | Bladder Cancer

Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)

Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)

Mar 16, 2022 | Bladder Cancer

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.

Apr 16, 2020 | Bladder Cancer, Merkel Cell Carcinoma, Non-Small Cell Lung Cancer

Recent Posts

  • ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
  • First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
  • FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
  • ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
  • Piper Sandler Annual Healthcare Conference

Quicklinks

  • Pipeline
  • Careers
  • News and Events
  • Investors
  • Contact

Follow Us

  •  Facebook
  •  Twitter
  •  LinkedIn

Legal

  • Privacy Policy
  • Legal Notice
  • Patent Notice
  • How-To-Use-Accessibe

© 2023 ImmunityBio, Inc. All Rights Reserved.

A member of the NantWorks ecosystem of companies

'Nantkwest’, ‘haNK’, ‘taNK’, ’t-haNK’, ‘ceNK’, ‘NK-92’, ‘Living Drugs in a Bag’, ‘Nature’s First Responder’, ‘Outsmart Your Disease’, and ‘Smart Therapies for Difficult Diseases’ are trademarks or registered trademarks of Nantkwest, ImmunityBio, Inc.

Anktiva is a registered trademark of ImmunityBio, Inc.

The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.

Sitemap